Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer

• Status: Unknown status
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

Anthracycline based regimens followed by a taxane (CALGB-9344 trial and NSABP-B28) or reversed (MD Anderson Adjuvant Trial) has already accepted as adjuvant therapy for node positive breast cancer. Also in this group of patients, data from BCIRG-001 trial had shown that six cycles of adjuvant TAC (docetaxel, doxorubicin and cyclophosphamide) is superior to standard FAC (5-FU, doxorubicin and cyclophosphamide ) combination in terms of both disease free and overall survival, while associated with a higher rate of febrile neutropenia. Then question arose whether it is better to use docetaxel and anthracycline in combination or sequence.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Liposomal doxorubicin

Criteria

Inclusion Criteria:

• pT1-3,pN1-3,M0, operable breast cancer

• Karnofsky >=80

• Pregnant test negative

Exclusion Criteria:

• Prior Chemotherapy with anthracyclines and / or Taxanes, except for Neoadjuvant therapy

• Prior breast radiation

• Bilateral breast cancer

• in-operable breast cancer

• Other health condition which may be contraindications for chemotherapy

• contraindications for Dexamethasone